Tasly Pharmaceutical Group (600535.SH) subsidiary receives drug registration certificate for indocyanine green for injection.

date
16:52 09/10/2026
avatar
GMT Eight
Tasly Pharmaceutical Group (600535.SH) announced that recently, its wholly-owned subsidiary Tianjin Tasly Zhijiao Pharmaceutical Co., Ltd. received the Drug Registration Certificate for Indocyanine Green for Injection approved and issued by the National Medical Products Administration. Indocyanine Green for Injection is clinically used for the diagnosis of various liver diseases such as cirrhosis, liver fibrosis, active hepatitis, occupational and drug-induced toxic liver disease, to assess the degree of liver damage and its reserve function; it can also be used for choroidal angiography to determine the location of choroidal disorders. The drug was registered and filed as a Class 3 chemical drug, and is deemed to have passed the generic drug consistency evaluation.
Tasly Pharmaceutical Group (600535.SH) announced that recently, its wholly-owned subsidiary Tianjin Tasly Pharmaceutical Group Zhijiao Pharmaceutical Co., Ltd. received the Drug Registration Certificate for Indocyanine Green for Injection approved and issued by the National Medical Products Administration. Indocyanine Green for Injection is clinically used for diagnosing various liver diseases such as cirrhosis, liver fibrosis, active hepatitis, and occupational and drug-induced toxic liver disease, to assess the degree of liver damage and its reserve function; it can also be used for choroidal angiography to determine the location of choroidal disorders. The drug was registered and declared as a Class 3 chemical drug, and is deemed to have passed the generic drug consistency evaluation.